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Background: Chronic pain is an important medical problem affecting hundreds of millions of people worldwide.
Mechanisms underlying the maintenance of chronic pain states are poorly understood but the elucidation of such
mechanisms have the potential to reveal novel therapeutics capable of reversing a chronic pain state. We have
recently shown that the maintenance of a chronic pain state is dependent on an atypical PKC, PKMζ, but the
mechanisms involved in controlling PKMζ in chronic pain are completely unknown. Here we have tested the
hypothesis that brain derived neurotrophic factor (BDNF) regulates PKMζ, and possibly other aPKCs, to maintain a
centralized chronic pain state.
Results: We first demonstrate that although other kinases play a role in the initiation of persistent nociceptive
sensitization, they are not involved in the maintenance of this chronic pain state indicating that a ZIP-reversible
process is responsible for the maintenance of persistent sensitization. We further show that BDNF plays a critical
role in initiating and maintaining persistent nociceptive sensitization and that this occurs via a ZIP-reversible
process. Moreover, at spinal synapses, BDNF controls PKMζ and PKCλ nascent synthesis via mTORC1 and BDNF
enhances PKMζ phosphorylaton. Finally, we show that BDNF signaling to PKMζ and PKCλ is conserved across CNS
synapses demonstrating molecular links between pain and memory mechanisms.
Conclusions: Hence, BDNF is a key regulator of aPKC synthesis and phosphorylation and an essential mediator of
the maintenance of a centralized chronic pain state. These findings point to BDNF regulation of aPKC as a potential
therapeutic target for the permanent reversal of a chronic pain state.Background
How acute injury transforms to chronic pain remains a
long-standing, unresolved question with important med-
ical ramifications. The natural history of most chronic
pain conditions suggests that achieving clinically mea-
ningful endpoints requires interventions aimed at tar-
geting or reversing pathological changes that maintain
sensitization in these chronic pain states. While studies
on plasticity of sensory neurons and CNS structures
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distribution, and reproduction in any mediumimplicated in the initiation of pain in preclinical models
[1-6], our understanding of molecular mechanisms that
maintain chronic pain states remains poor.
Recent advances in understanding how neural circuits
maintain long-lasting plasticity may offer insights into
how pain becomes chronic [5,6]. Analogous to pain, the
encoding of memory engrams in CNS structures is sepa-
rated into initiation and maintenance phases. Initiation
of engram encoding requires protein synthesis [7] and
an atypical protein kinase C (aPKC) called PKMζ [8].
Maintenance of the engram is has been linked to PKMζ
as PKMζ represents the only known kinase whose activ-
ity is required for the maintenance of late-long-term po-
tentiation (LTP) and long-term memory [8], although
recent studies have called this hypothesis into question
[9,10]. We have demonstrated that the pharmacologyentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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parallels memory engram encoding in the CNS wherein
the maintenance phase is critically dependent on PKMζ
[11]. These findings have been expanded upon by several
groups [12-15] showing that spinal PKMζ is a crucial kin-
ase for the maintenance of pain states that are no longer
dependent on afferent input [13]. This conclusion is sup-
ported by a lack of effect of spinal PKMζ inhibitors in
peripheral nerve injury models wherein afferent input is
continuous as a result of the nerve injury [12,15]. On the
other hand, following peripheral nerve injury, PKMζ in
other CNS regions such as the anterior cingulate cortex,
plays a key role in spontaneous pain evoked by injury
[12,15].
Hence, PKMζ, and possibly other aPKCs, are key tar-
gets for the maintenance of chronic pain states and for
the maintenance of long-term memory; however, re-
markably little is known about how PKMζ is regulated at
CNS synapses. Even less is known about the regulation
of other aPKCs, such as PKCλ in the CNS. The impor-
tance of this gap in knowledge is driven home by recent
controversy in the field wherein the use of ZIP as a spe-
cific PKMζ inhibitor has been called into question [9,10].
Brain-derived neurotrophic factor (BDNF), like PKMζ,
plays a key role in the initiation and maintenance of LTP
and long-term memories [16] and is an important medi-
ator of pain in the dorsal horn [17-21]. Hence, we hy-
pothesized that BDNF, via its receptor: tyrosine receptor
kinase type B (trkB), might play an important role in
regulating PKMζ and possibly other aPKCs. Our findings
indicate that BDNF stimulates PKMζ phosphoryla-
tion and synthesis of PKMζ and PKCλ via activation of
PDK1/AKT/mTOR signaling at spinal and cortical sy-
napses. Moreover, we show that BDNF is required for
the initiation and maintenance of a chronic pain state
strongly implicating a BDNF/aPKC signaling module as
a key regulator of centralized chronic pain. Therefore, we
have elucidated the first neurotransmitter/neurotrophin
involved in spinal, synaptic aPKC regulation and linked
this system to the initiation and maintenance of a central
engram encoding a chronic pain state.
Results
Maintenance of persistent sensitization is independent of
CaMKIIα and MEK/ERK signaling
We have previously used a model of persistent sen-
sitization, based on rat models of hyperalgesic priming
[22], to demonstrate a role for PKMζ in maintenance of
a chronic pain state [11]. A key feature of this model is
that after the resolution of an initial allodynic state, a
subsequent nociceptive hypersensitivity can be revealed
by hindpaw injection of a normally subthreshold dose of
prostaglandin E2 (PGE2), causing a prolonged allodynia,
or spinal administration of the mGluR1/5 agonist DHPG,causing pronounced nocifensive behaviors [11,22]. In
naïve animals, PGE2 and DHPG only elicit transient
allodynia or nocifensive behaviors, respectively. Hence,
this model establishes a persistent sensitization that can
be clearly divided into an initiation (induction of priming
with interleukin 6 (IL-6)) and maintenance phase (PGE2)
that persists for long periods of time. Consistent with
concepts governing memory encoding and the pharma-
cology of LTP, our previous findings demonstrate that
persistent nociceptive sensitization initiation requires spi-
nal protein synthesis and is reversible by the aPKC inhibi-
tor ZIP whereas maintenance is solely dependent on ZIP
reversible process [11].
We previously used staurosporine, which inhibits PKC
and PKA but not aPKC to demonstrate a specific role
for PKMζ in maintenance of persistent sensitization [11].
However, these experiments did not assess a possible role
of CaMKIIα or MEK/ERK signaling in initiation or main-
tenance of persistent sensitization. To test this we used
the CaMKIIα peptide inhibitor CamKIINTide in a cell
permeable myristoylated (myr) form (or the non-myr pep-
tide as a negative control), the small molecule CaMKIIα
inhibitor KN93 and the MEK inhibitor U0126. Impor-
tantly, CamKIINTide has been previously reported to
reverse late-LTP [23]. Consistent with previous reports
suggesting a role of CaMKIIα in the initiation of inflam-
matory pain states [24,25], myr-CamKIINTide reversed
IL-6-induced allodynia when administered intrathecally
(i.t.) at the same time as intraplantar (i.pl.) IL-6 (Figure 1A).
Moreover, this treatment blocked precipitation of per-
sistent sensitization to PGE2 injection into the same hind-
paw 6 days later (Figure 1A). Hence, CaMKIIα is involved
in the initiation of persistent sensitization. In contrast,
when either myr-CamKIINTide (Figure 1B) or KN-93
(Figure 1C) was injected i.t. after the resolution of the ini-
tial IL-6-induced allodynia (maintenance phase), neither
compound was capable of reversing persistent sensiti-
zation revealed by i.pl. PGE2 injection. Hence, like protein
synthesis inhibitors [11], inhibition of CaMKIIα does not
reverse an established, centralized pain state. Identical
experiments were conducted with U0126 and, while
U0126 was capable of inhibiting initiation of persist-
ent sensitization (Figure 1D), it had no effect on main-
tenance (Figure 1E). Therefore, we conclude that neither
CaMKIIα nor MEK/ERK, but rather a ZIP-reversible pro-
cess is required for the maintenance of persistent sensiti-
zation at dorsal horn synapses.
BDNF is sufficient to induce persistent sensitization and is
required for the initiation and maintenance of persistent
sensitization
I.t. injection of BDNF is known to induce a long-lasting
allodynic state in mice [26] but it is not known if BDNF
can induce a ZIP-reversible persistent sensitization as
Figure 1 Lack of involvement of CaMKIIα or MAPK in persistent sensitization. A) IL-6 was injected into the left hindpaw (i.pl.) of mice and
myr-CamKIINTide (peptide CaMKIIα inhibitor) or the non-myristolyated control were injected i.t. at the same time testing the initiation of
persistent sensitization. Hindpaw mechanical thresholds were measured at indicated time points. Myr-CamKIINTide inhibited allodynia induced by
IL-6 injection (left) and attenuated PGE2-precipitated persistent sensitization (right). B) On the other hand, Myr-CamKIINTide administered i.t. on
day 4 after IL-6 injection had no effect on PGE2-precipitated persistent sensitization. C) Likewise, no effect was observed in the same experimental
paradigm with the small molecule CaMKIIα inhibitor KN93. D) IL-6 was injected i.pl. and the MEK inhibitor U0126 or VEH control were injected i.t.
at the same time testing the initiation of persistent sensitization. U0126 inhibited allodynia induced by IL-6 injection (left) and attenuated
PGE2-precipitated persistent sensitization (right). E) However, U0126 given i.t. 4 days after IL-6 had no effect on PGE2-precipitated persistent
sensitization. All experiments N = 6. * p < 0.05, ** p < 0.01, *** p < 0.001, two way ANOVA with Bonferroni post hoc test.
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i.t. induced mechanical allodynia in the hindpaws of
mice lasting for at least 3 days and resolving within 5
days (Figure 2A). 8 days following BDNF injection we
injected the aPKC inhibitor myr-ZIP (ZIP) or a myr-
scrambled peptide (Scr ZIP) i.t.. Because a previous studyhad suggested that the effects of ZIP may only last for 2
days [27], we waited for 6 days following i.t. injection of
ZIP to assess subsequent PGE2 precipitated persistent
sensitization. Mice that received ZIP on day 8 showed
only a transient allodynia following PGE2 injection where-
as mice receiving Scr ZIP demonstrated at least 24 hrs of
Figure 2 BDNF is sufficient to establish a ZIP-reversible persistent sensitization and is required for initiation and maintenance of
persistent sensitization. A) BDNF was injected i.t. causing 3 days of allodynia in mice (left) and myristoylated-ZIP or Scr-ZIP were injected i.t.
8 days following BDNF injection. ZIP treatment blocked PGE2-precipitated persistent sensitization (right). B) IL-6 was injected i.pl. and the BDNF
sequestering agent, TrkB/Fc was given i.t. at the same time, dose-dependently blocking IL-6-induced allodynia (left) and PGE2-precipitated
persistent sensitization (right). C) A single i.t. treatment with TrkB/Fc 4 days after i.pl. IL-6 injection was sufficient to attenuate PGE2-precipitated
persistent sensitization. D) The small molecule TrkB antagonist, ANA-12) given i.p. at the same time as i.pl. Il-6 and again 24 and 48 hrs later
blocked IL-6-induced allodynia (left) and PGE2-precipitated persistent sensitization (right). E) Systemic treatment with ANA-12 4 and 5 days after i.
pl. IL-6 injection reduced PGE2-precipitated persistent sensitization. All experiments N = 6. * p < 0.05, ** p < 0.01, *** p < 0.001, two way ANOVA
with Bonferroni post hoc test.
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Hence BDNF is sufficient to stimulate a ZIP-reversible
persistent sensitization.
We then asked whether BDNF sequestration or block-
ade of TrkB would inhibit IL-6-induced initiation and/
or maintenance of persistent sensitization. To test ini-
tiation, the BDNF sequestering agent, TrkB/Fc was
injected i.t. at the same time as i.pl. IL-6. TrkB/Fc dose-
dependently disrupted IL-6-induced allodynia and PGE2
precipitated persistent sensitization (Figure 2B). Impor-
tantly, when TrkB/Fc was injected i.t. following the
resolution of IL-6-induced allodynia, this treatmentsignificantly reversed the maintenance of persistent
sensitization (Figure 2C) similar to previous observations
with ZIP. If this effect was dependent on BDNF inter-
action with TrkB, we hypothesized that administration
of the small molecule TrkB antagonist ANA-12 should
achieve the same effect [28]. ANA-12, which has systemic
availability and penetrates the CNS [28], was injected
intraperitoneal (i.p.) at the time of IL-6 injection and
again 24 and 48 hrs later. This treatment significantly
reversed IL-6 induced allodynia and persistent sensitiza-
tion revealed by PGE2 injection on day 7 following IL-6
(Figure 2D). Remarkably, when ANA-12 was given i.p. on
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sensitization was precipitated with PGE2 on day 7 (a time
where ANA-12 should be cleared from the CNS), persist-
ent sensitization was reversed (Figure 2E). Hence, BDNF,
acting via trkB, is required for the initiation and mainten-
ance of persistent sensitization.
BDNF increases PKMζ protein levels and phosphorylation
at spinal synapses
Having established a role for BDNF in initiation and
maintenance of persistent sensitization, we asked if
BDNF regulates PKMζ and/or other aPKCs at spinal
synapses. We investigated other aPKCs because it has
recently been suggested that PKMζ is not required for
the maintenance of late-LTP or long-term memory using
genetic knockouts [9,10]. It has also been shown that
ZIP blocks PKMζ and PKCλ [10] indicating that ZIP
affects all aPKCs. Finally, ZIP still effectively reverses
late-LTP and long-term memory in mice lacking PKMζ
suggesting a functional redundancy of aPKCs in plasti-
city pathways [9,10,29]. We first assessed aPKC mRNA
expression and protein localization in the mouse spinal
cord. As we have shown previously in rat [15], PKCζ
mRNA was not expressed in the mouse spinal cord
whereas PKCλ and PKMζ were both robustly expressed
by qPCR (Figure 3B). Likewise consistent with previous
findings in rat [14], aPKC protein localized largely to the
dorsal horn of the spinal cord and this immunoreactivity
was found exclusively in neurons (Figure 3A inset). Be-
cause the immunostaining does not allow for distingui-
shing between PKMζ and PKCλ we resorted to isolation
of synaptoneurosomes (SNSs, [30]) from mouse lumbar
spinal cord where PKMζ and PKCλ could be analyzed
seperately by Western blot. These SNS preparations
were enriched in GluN1 mRNA [31], were βIII-tubulin
mRNA poor (Figure 3B, [32]) and at least 10 fold enriched
in PSD-95 protein consistent with enrichment of spinal
synaptic structures using this technique (Figure 3B).
To determine if BDNF regulates aPKC protein levels
at spinal synapses we stimulated SNSs with increasing
concentrations of BDNF. Because previous studies have
suggested a role for mTOR in regulating PKMζ forma-
tion in LTP [33] and because BDNF is known to regulate
mTOR in hippocampus [34], we also assessed signa-
ling components of the mTOR pathway in these experi-
ments. BDNF increased mTOR S2481 phosphorylation
consistent with activation of mTORC2 [35] at spinal
synapses with BDNF (Figure 3C). Likewise, BDNF in-
creased AKT phosphorylation at T308 (PDK1 site) and
S473 (mTORC2 site) and BDNF increased phosphoryl-
ation of the mTORC1 target Thr389 residue on p70 S6
Kinase (p70, [36] Figure 3C). Consistent with engagement
of mTORC1-dependent protein synthesis, PKCλ, PKMζ
and CaMKIIα protein levels were also increased by BDNFin spinal SNSs (Figure 3C). These effects were time
dependent with changes in phosphorylation occurring
largely at 15 min of BDNF stimulation and resolving
by 30 min. The exception was T308 phosphorylation
of AKT (PDK1 site), which persisted for the full 30 min
of BDNF exposure (Figure 4A). We also observed long-
lasting changes in total amounts of PKCλ, PKMζ and
CaMKIIα (Figure 4A), again consistent with a protein
synthesis-dependent process. These effects are likely not
due to aPKC regulation in sensory afferent terminals be-
cause exposure of sensory neurons in culture to BDNF led
to robust activation of AKT without any corresponding
change in aPKC levels (data not shown).
Because total levels of PKMζ were changed by BDNF
exposure to SNSs, we performed experiments where pro-
tein synthesis could not occur to assess whether BDNF
also changed PKMζ phosphorylation in a persistent fash-
ion. In the absence of amino acids, BDNF failed to in-
crease total PKMζ level in spinal SNSs, however, under
these conditions, BDNF robustly increased AKT T308
and PKMζ T410 phosphorylation (Figure 4B). Because
both of these phospho sites are acceptors for PDK1 activ-
ity these findings suggest that BDNF stimulates PDK1 to
achieve persistent increases in downstream target phos-
phorylation. Hence, BDNF persistently increases PKMζ
protein levels and phosphorylation at spinal synapses.
BDNF stimulates eIF4F complex formation and aPKC
nascent synthesis at spinal synapses
The results presented above suggest that aPKCs are syn-
thesized as a result of BDNF action on spinal synapses.
To pursue this idea with more rigor, we first asked if
BDNF increases formation of the 50 cap binding complex
composed of eIF4E, eIF4A and eIF4G, called eIF4F, at
spinal synapses. This complex is involved in promoting
cap-dependent protein synthesis and occurs downstream
of mTORC1 activation [37]. Using m7-GTP beads, we
performed 50 cap pulldown assays on SNSs stimulated
with BDNF for 15 min. BDNF increased eIF4A pulldown
and decreased 4EBP association with eIF4E, consistent
with BDNF inducing formation of the eIF4F complex
at spinal synapses (Figure 5A). This effect was com-
pletely blocked by inclusion of temsirolimus indicat-
ing that BDNF promotes eIF4F complex formation in
an mTORC1-dependent fashion (Figure 5A).
We next asked if BDNF increases nascent synthesis of
aPKCs in an mTORC1-dependent fashion. To do this,
we first assessed whether aPKC mRNA was found at
spinal synapses. SNSs were prepared and mRNA levels
were assessed by qPCR. PKMζ and PKCλ, but not PKCζ,
mRNA was detected in spinal SNSs demonstrating that
these SNSs are capable of supporting nascent synthesis
of PKCλ and PKMζ and supporting the notion that
PKCλ and PKMζ mRNAs are transported to synapses in
Figure 3 PKCλ and PKMζ protein localize to central neurons in the dorsal horn and are increased by BDNF treatment. (A) Slices were
prepared from mice and stained with an atypical PKC (aPKC) antibody (red) and the neuronal marker (found in soma and post-synaptic sites)
SAP-102 (green). The top panel shows that aPKC immunoreactivity is localized primarily to the spinal dorsal horn. Lower panels (from inset) show
that aPKC immunoreactivity is localized almost exclusively to neurons in the dorsal horn. (B) qPCR was used to assess mRNA expression of aPKC
isoforms in spinal cord and kidney (N = 3). Spinal SNSs were prepared and mRNA or protein was isolated. Spinal SNSs were enriched for GluN1
mRNA and were βIII tubulin poor, they were likewise enriched in PSD95 protein as shown by Western blotting compared to equal protein
concentration of whole spinal cord homogenate (input). C) SNSs were isolated from mouse lumbar spinal cord and exposed to increasing
concentrations of BDNF for 15 min. BDNF dose-dependently increased mTOR, AKT and p70S6 kinase (p70) phosphorylation when standardized to
total protein levels. BDNF also increased total levels of PKCλ PKMζ and CaMKIIα when compared to loading control βIII tubulin (N = 6). * p < 0.05,
*** p < 0.001, one way ANOVA with Bonferroni post hoc test compared to Veh.
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PKCλ and PKMζ mRNA are found at synapses, we used
azidohomoalanine (AHA), a click-chemistry compatible
methionine analogue that does not interfere with other
cellular processes [38], to assess nascent synthesis ofPKCλ and PKMζ. The methionine stores were depleted
in spinal SNSs by inclublting them in methionine free
media for 15 min. This was followed by stimulation of the
SNSs with BDNF in the presence of AHA for 30 min.
aPKC proteins were immunoprecipitated and labeled with
Figure 4 Time course of BDNF regulation of aPKCs in spinal SNSs. SNSs were prepared from mice and treated with BDNF for indicated time
points. A) BDNF transiently increased mTOR, AKT (S473) and p70S6 kinase (p70) phosphorylation but led to a longer lasting increase in AKT
phosphorylation at T308 and in total levels of PKCλ, PKMζ and CaMKIIα (N = 6). B) To assess whether BDNF increased PKMζ phosphorylation, SNSs
were treated with BDNF in the absence of amino acids. BDNF treatment led to a persistent increase in AKT (T308, PDK1 site) and PKMζ (T410,
PDK1 site) phosphorylation (N = 6). * p < 0.05, ** p < 0.01, one way ANOVA with Bonferroni post hoc test compared to Veh.
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incorporated AHA (e.g. nascently synthesized proteins).
Remarkably, BDNF led to a robust increase in nascently
synthesized PKCλ and PKMζ that was completely abro-
gated by mTORC1 inhibition (Figure 5C). Hence, BDNF
induces PKCλ and PKMζ nascent synthesis via an increase
in eIF4F complex formation downstream of mTORC1 ac-
tivation at spinal synaptic structures.BDNF increases mTORC1 activity and aPKC formation at
cortical synapses
Having shown that BDNF regulates PKCλ and PKMζ
formation in an mTORC1-dependent fashion at spinalsynapses we then asked it BDNF also achieves similar ef-
fects at cortical synapses where both BDNF and PKMζ
(and possibly PKCλ [9,10,29]) are known to play an im-
portant role in LTP and long-term memory maintenance
[8,16]. By qPCR, PKCλ and PKMζ mRNA localized
to cortical SNSs as shown above for spinal SNSs and
these cortical SNSs were also enriched for GluN1 mRNA
(Figure 6A). Likewise identical to observations in spinal
SNSs, BDNF stimulated an increase in mTOR S2481,
AKT T308 and S473 and p70 phosphorylation (Figure 6B).
BDNF also increased CaMKIIα, as shown previously [39],
and PKCλ and PKMζ protein levels (Figure 6B). Hence,
BDNF regulation of PKMζ formation is conserved across
CNS synapses (Figure 7).
Figure 5 BDNF enhances eIF4F complex formation and nascent
synthesis of PKCλ and PKMζ in spinal SNSs in an mTOR-
dependent fashion. SNSs were prepared from mouse lumbar spinal
cord and treated with or without BDNF (100 ng/ml) or the mTORC1
inhibitor temsirolimus (Tem, 100 nM). A) Following 15 min treatment
with the indicated conditions, 50m7-GTP pulldown assays were
performed and eIF4A, 4EBP and eIF4E were assessed by Western
blot. BDNF treatment led to an increase in eIF4A pulldown and a
decrease in 4EBP pulldown in an mTORC1-dependent fashion
(N = 6). B) SNSs were assessed for aPKC mRNA expression by qPCR.
SNSs contained PKMζ and PKCλ mRNA but not PKCζ (N = 3). C) SNSs
were treated with BDNF +/− Tem in the presence of AHA to tag
nascently synthesized proteins for 30 min. AHA aPKC was
immunoprecipitated and AHA was labeled with biotin using click-
chemistry. BDNF treatment led to an increase in nascently
synthesized PKCλ and PKMζ in an mTORC1-dependent fashion
(N = 6). * p < 0.05, ** p < 0.01, one way ANOVA with Bonferroni post
hoc test compared to Veh.
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While PKMζ is well-recognized as a potential molecular
mechanism for the maintenance of LTP and long-term
memory [8,40] and its important role in pain plasticity
has recently been elucidated [11-15], neurotransmitter
systems involved in the regulation of PKMζ have not
been described in detail. Moreover, the specific role of
PKMζ in CNS plasticity has recently been called into
question with PKCλ emerging as a potential redundant
mechanism in CNS plasticity [9,10,29]. Here we demon-
strate that BDNF promotes persistent sensitization via
a ZIP-reversible mechanism. Moreover, we show that
BDNF is critical for both the initiation and maintenance
of persistent sensitization, a role that it may uniquely
share with an aPKC-dependent process [11,13]. Lin-
ked to these in vivo findings, we further demonstrate
that BDNF regulates PKCλ and PKMζ synthesis via
an mTORC1-dependent pathway and PKMζ phosphory-
lation via PDK1 at spinal and cortical synapses. Import-
antly, we show definitively, for the first time, that both
PKCλ and PKMζ are synthesized in an activity-dependent
fashion at synaptic sites. Therefore, BDNF plays a key role
in regulating aPKCs in the pain pathway elucidating a
hitherto unrecognized pathway regulating the mainten-
ance of a centralized chronic pain state.
PKMζ is an atypical PKC that was first recognized as
a constitutively active kinase that may play a role in
maintenance of late-LTP [8,41]. Because PKMζ lacks a
regulatory region, once translated, and phosphorylated
by PDK1, the kinase has the potential to maintain au-
tonomous activity over extended periods of time, satis-
fying theoretical considerations for a kinase-mediated
mechanism maintaining late-LTP [8]. This hypothesis
has been borne-out by a body of subsequent work dem-
onstrating a key role for PKMζ in maintaining late-LTP
and also long-term memory [42,43]. While parallels bet-
ween molecular mechanisms of long-term memory and
Figure 6 BDNF activates mTOR and increases PKCλ, PKMζ and CaMKIIα protein in cortical SNSs. A) qPCR was used to assess aPKC mRNA
expression in whole cortex samples (Input) and in cortical SNSs SNSs. PKMζ and PKCλ mRNA were found in cortex and cortical SNSs but not
PKCζ. GluN1 mRNA was enriched in cortical SNSs (N = 3). B) SNSs were prepared from mouse cortex and stimulated with 100 ng/ml BDNF for
15 min. Treatment led to an increase in mTOR, AKT and p70S6 kinase (p70) phosphorylation as well as increased levels of total PKCλ, PKMζ and
CaMKIIα (N = 6). * p < 0.05, ** p < 0.01, *** p < 0.001, student’s t-test.
Figure 7 BDNF regulation of aPKCs at central synapses.
Summary cartoon of major findings presented here. At spinal
synapses, BDNF activated trkB leading to increased PI3K and PDK1
activity. This stimulates aPKC phosphorylation at T410 and an
increase in AKT activity thereby stimulating mTORC1. This increase in
mTORC1 activity leads to an increase in eIF4F complex formation
resulting in an enhancement of aPKC translation at spinal synapses.
Data from cortical SNS preparations strongly suggest that this
signaling complex engaged by BDNF resulting in regulation of PKMζ
is present across central synapses.
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has PKMζ been elucidated as a potential target for main-
tenance of chronic pain states. PKMζ appears to play
different roles in different anatomical locations in the
pain pathway. PKMζ in sensory neurons is important for
nerve growth-factor mediated hyperexcitability [44].
PKMζ in the anterior cingulate cortex plays a key role in
regulating tonic-aversive aspects of chronic neuropathic
pain [12,15]. Interestingly, a ZIP-reversible process in
the spinal cord appears to play little, if any role in main-
taining chronic neuropathic pain [12,15], perhaps be-
cause this chronic pain state is critically dependent on
ongoing afferent input to the spinal dorsal horn [45]. In
contrast, in chronic pain states wherein afferent input
resolves but hypersensitivity either persists or can be re-
kindled by a normally subthreshold stimulus (e.g. persis-
tent sensitization [11], CFA-induced inflammation [22]
or chronic post ischemic pain [13,46]) the maintenance
of this pain state is reversed by spinal injection of ZIP.
Our present findings expand on these previous results
demonstrating that while CaMKIIα and MEK/ERK sig-
naling is required for initiation of persistent sensiti-
zation, these kinases do not play an active role in the
maintenance phase of persistent sensitization. These fin-
dings can be viewed as in contrast to other models, such
as CFA, formalin, and/or incision, wherein ERK [47,48]
and CaMKIIα [24] play an important role in initiation
and maintenance of a continuous hypersensitive pain
state. Such differences, as mentioned above, may be re-
lated to afferent input engaged by these stimuli, which
presumably resolves during the maintenance phase of
the persistent sensitization model. We feel it is import-
ant to point out that i.t. drug applications during the
maintenance phase are made when the mice show no
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pounds were to be given at the same time as PGE2 in-
jection an inhibitory effect might be expected because
afferent input would be re-engaged, likely utilizing prim-
ing-dependent peripheral mechanisms that have recently
been elucidated [49]. These results, combined with our
previous findings, strongly implicate aPKCs as the sole
family of kinases responsible for the maintenance of per-
sistent sensitization.
Despite the emerging role of PKMζ and potentially
PKCλ in pain plasticity, mechanisms involved in aPKC
regulation in the pain pathway are nearly completely un-
known. We hypothesized that BDNF might play a key
role in regulating aPKCs. This hypothesis was based on
a known role of BDNF in pain states consistent [18-20]
with the known effects consistent with an involvement
of aPKCs. While BDNF can have several sources in the
spinal dorsal horn, acutely it is released from nociceptors
synapsing in the outer lamina of the dorsal horn [17,19]
where it regulates inflammatory but not neuropathic
pain [19]. BDNF also plays an important role in regulat-
ing LTP at dorsal horn synapses [20] consistent with the
known role of BDNF in LTP in other CNS regions [16].
These findings, combined with our present results, are
consistent with a model wherein BDNF released from
nociceptive endings in the spinal dorsal horn initiates
signaling cascades that lead to the formation and phos-
phorylation of aPKCs at these synapses. Although spinal
BDNF plays a role in neuropathic pain, as mentioned
below, this has been linked to release from microglia
[50,51] and not nociceptor terminals because neuro-
pathic pain develops normally in mice lacking BDNF ex-
pression in nociceptors [19]. This finding is consistent
with previous findings showing a limited role of a spinal
ZIP-reversible process in neuropathic pain. We cannot,
however, rule out an effect of microglial BDNF in our
experiments. In that regard, BDNF is also known to play
an important role in microglial activity [21] and neuro-
pathic pain where it regulates GABAergic modulation
of spinal circuits through disruption of Cl- homeostasis
[51,52]. Interestingly, this mechanism appears to be
shared in morphine-induced hyperalgesia [53]. Our find-
ings from spinal SNS experiments clearly demonstrate
that BDNF applied exogenously is capable of stimulating
synthesis of PKCλ and PKMζ and phosphorylation of
PKMζ. Whether BDNF released from microglia is incap-
able of achieving these effects at spinal synapses will
have to await further experimentation. Although BDNF
can have trkB-independent actions [54], we surmise
that the effects of BDNF in our experiments were me-
diated by trkB due to the effect of the trkB antagonist
ANA-12 [28].
An important implication of our current findings
is that BDNF not only plays a role in initiating acentralized chronic pain state but that it also plays an
active role in maintaining such a pain state via regula-
tion of aPKCs. If this is the case, what is the source of
BDNF? It is unlikely to be derived from presynaptic re-
lease from nociceptors because these sensory neurons
are unlikely to be active after the resolution of IL-6-in-
duced allodynia. It is also unlikely that microglia are the
source because this would be inconsistent with the
neuropathic pain findings for ZIP [12,13,15]. Important
clues might be gleamed from the LTP literature wherein
both pre- and post-synaptic release of BDNF regulates
consolidation of late-LTP [55-57]. Interestingly, this
likely involves alternatively spliced isoforms of BDNF in
hippocampus [58] facilitating the possible recognition of
such a mechanism being engaged in the spinal dorsal
horn. While these experiments are outside of the scope
of the present findings, this is likely to be a fruitful
area of future research to gain a better understanding
of maintenance mechanisms of a centralized chronic
pain state.
Another important question raised by our findings
relates to the dependence of maintenance of persistent
sensitization on aPKCs but not protein synthesis. If
BDNF regulates both PKCλ and PKMζ synthesis and
PKMζ phosphorylation and initiation and maintenance
of persistent sensitization are dependent on both aPKCs
and BDNF but only initiation is dependent on protein
synthesis, how is this seeming contradiction resolved?
One possible explanation is that in the absence of protein
synthesis, BDNF regulation of PKMζ phosphorylation is
sufficient to maintain the chronic pain state. Interestingly,
in spinal SNSs, BDNF stimulation of mTORC1 activity
was transient whereas PDK1 mediated phosphorylation of
both AKT and PKMζ was persistent. Hence, it is physiolo-
gically feasible that in the absence of protein synthesis,
BDNF-mediated phosphorylation of PKMζ is sufficient to
maintain persistent sensitization. Another possibility is
that PKMζ, and possibly PKCλ, has an exceptionally long
half-life at synapses. In this scenario, despite blockade of
protein synthesis over long periods, aPKCs formed via
previous protein synthesis would be capable of overcom-
ing a lack of new protein availability due to its long half-
life. Our preliminary observations (Melemedjian, Ghosh
and Price, unpublished observations) support this model
but ultimately require further experimentation. However,
it is clear that BDNF can maintain late-LTP when protein
synthesis is inhibited via a PKMζ-dependent mechanism
[59] suggesting that similar mechanisms may be at play in
the setting of persistent sensitization.
Importantly, we demonstrate that BDNF regulates aPKC
formation in cortical SNSs in an analogous fashion to
spinal SNSs. Insofar as both the maintenance of a central-
ized chronic pain state and long-term memory require
both BDNF [60] and PKMζ [8], and considering that we
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structures, this illustrates the potential existence of a con-
served pathway for the maintenance of synaptic plasticity
from pain to memory. We propose that this has profound
implications for understanding how mechanisms of plasti-
city evolved in central nervous systems and we suggest
that these mechanisms might have first evolved for the
most rudimentary neural function: protecting the organ-
ism against potentially lethal tissue injury. An important
point moving forward will be to unveil how different
aPKC isoforms contribute to pain plasticity through gen-
etic models, as we have recently reviewed [29]. This need
is highlighted by the recent findings from the learning and
memory literature showing that genetic removal of PKMζ
fails to affect learning and memory despite the continued
efficacy of ZIP in these animals, suggesting a potential re-
dundant role of PKCλ in these pathways [9,10]. It will be
crucial to carefully examine the role of PKCλ in plasticity
moving ahead.
In closing, we reveal that BDNF regulates the forma-
tion of PKCλ and PKMζ and phosphorylation of PKMζ
and that BDNF/aPKC signaling forms a signaling axis re-
quired for the maintenance of a centralized chronic pain
state. Our results imply that spinally directed therapeu-
tics targeting BNDF and/or aPKCs might offer disease-
modifying effects on certain chronic pain states in humans
that are currently only treated by palliative management.
The generation of such a class of therapeutics would have
profound implications for the treatment of chronic pain.
Methods and materials
Experimental animals
All animal procedures were approved by the Institutional
Animal Care and Use Committee of The University of
Arizona and were in accordance with International Asso-
ciation for the Study of Pain guidelines. Male ICR mice
(20–25 g; Harlan) were used for all studies.
Mechanical testing
Animals were treated as described previously [11]. In
brief, animals were placed in acrylic boxes with wire
mesh floors, and baseline mechanical withdrawal thresh-
olds of the left hindpaw were measured after habituation
for 1 h using the up-down method [61]. The experi-
menter making measurements was always blinded to the
experimental conditions. For day 1 experiments with IL-
6, IL-6 was injected into the plantar surface of the left
hindpaw in a volume of 25 μl. For day 1 experiments
with BDNF, BDNF was injected intrathecally (i.t.) in a
volume of 5 μl. For intrathecal treatments on day 1,
drugs were injected immediately after intraplantar (i.pl.)
injections under brief (<3 min) isoflurane anesthesia in a
volume of 5 μl [62]. For day 1 experiments with ANA-
12, ANA-12 was injected intra-peritonially (i.p.) on day0, 1 and 2 following IL-6 injection. For experiments with
intrathecal treatments on day 4 or later, mice were
tested before i.t. injection to assure that allodynia had
completely resolved. I.T. injections were done at the in-
dicated time points under isoflurane anesthesia as de-
scribed above. For day 4 experiments with ANA-12,
ANA-12 was injected i.p. on day 4 and 5 following IL-6
injection. PGE2 (100 ng) was injected on day 6 or later
in the plantar surface of the left hindpaw in a volume of
25 μl. Allodynia testing was then done at the time points
indicated in the text.
PCR
Total RNA was extracted from tissue and synaptosomal
preparations the RNeasy mini kit (#74104 QIAGEN,
Valencia, CA, USA) according to the manufacturer’s in-
structions. RNA quantification and purity were tested
using a NanodropW spectrophotometer. 1 μg of total
RNA was used for cDNA synthesis with iScript™ Reverse
Transcription Supermix for RT-qPCR kit (#170-8890
Biorad). RT-PCR reactions were performed on an ABI
7500 Fast Real-time PCR System with SYBR Green
PCR master mix (#4309155 Applied Biosystems, Life
Technologies, Carlsbad, CA, USA) using default two-
step (95°–60°) amplification. All primer pairs were tested
by running 3–4 fold dilution across at least 5 dilution
points. Primers only passed if they had a calculated effi-
ciency between 97–103% with an R2 value greater than
0.98 and had a single, shoulder-free peak upon melt
curve analysis. Primer sequences are given in Table 1.
Reactions were run in triplicate; measurements are
based on at least three independent samples. No-RT and
Cq dilution controls were routinely performed to check
for genomic DNA and inhibitory contamination respect-
ively. Melt curves were performed with each run to insure
specific amplification products. Each reaction was normal-
ized to the expression of glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH). Expression numbers given in the
paper were calculated by arbitrarily assigning GAPDH a
value of 220 and calculating the expression relative to
GAPDH. GAPDH-normalized values were compared with
normalization to Eef1A and Rpl29 to ensure controls and
comparative data were consistent (data not shown).
Synaptoneurosome preparation and treatment
Spinal cord and cortical synaptoneurosomes (SNS) were
prepared from 3-weeks-old male ICR mice as previously
described [30]. Briefly, dissected spinal cords or cortices
were homogenized at on ice in homogenization buffer
(in mM) 118 NaCl, 4.7 KCl, 1.2 MgSO4, 2.5 CaCl2 and
1.53 KH2PO4, 212.7 glucose pH 7.4], supplemented with
Complete protease inhibitors (Sigma, St. Louis, MO) and
40 U/ml recombinant human RNase inhibitor (Life tech-
nologies, Grand Island, NY). Samples were successively
Table 1 Primer sequences used for qPCR experiments
Gene Forward primer Reverse primer Size
GAPDH AGGTCGGTGTGAACGGATTTG GGGGTCGTTGATGGCAACA 95
βIII Tubulin TAGACCCCAGCGGCAACTAT GTTCCAGGTTCCAAGTCCACC 127
PKCλ CCATGTGTACCAGAGCGTCCT TGTGGCCATTTGCACAATACA 106
PKCζ CAGGGACGAAGTGCTCATCA CACGGCGGTAGATGGACTTG 95
PKMζ AGCAGAGAAAGCCGAGTCCA TTAAAGCGCTTGGCTTGGAA 96
GluN1 ATGCACCTGCTGACATTCG TATTGGCCTGGTTTACTGCCT 142
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mesh filters (Millipore, Bedford, MA) and centrifuged at
1000 × g for 20 min. The pelleted SNS were suspended in
DMEM/F12 (Life technologies, Grand Island, NY) tissue
culture media supplemented with Complete protease in-
hibitors and RNase inhibitor. Some experiments were
carried out in homogenization buffer to prevent protein
synthesis since this buffer does not contain amino acid.
The resuspened SNS were then treated with various con-
cetrations of BDNF (R&D Systems, Minneapolis, MN) for
15 or 30 min at 37°C. SNS were centrifuged at 20000 × g
for 2 min, the pellet was resuspended in lysis buffer
(50 mM Tris HCl, 1% Triton X-100, 150 mM NaCl, and
1 mM EDTA at pH 7.4), ultrasonicated and centrifuged at
20000 × g for 15 min. The supernatant was collected and
assayed using Western blot analysis.
Nascent aPKC synthesis assay
SNS were suspended in methionine-free media (cat #
21013–024, Life technologies, Grand Island, NY) and
pretreated with vehicle or temsirolimus (100 nM, LC
Labs, Woburn, MA) for 15 min at 37°C. Azidohomo-
alanine (AHA) is a methionine analogue that cells can
incorporate into nascentlly synthesized protein. AHA
(50 μM, Life technologies, Grand Island, NY) was added
to the SNS suspension and incubated at 37°C for 30 min.
SNS were then centrifuged at 20000 × g for 2 min and
lysis buffer was added to the pellet. Protein was extracted
by ultrasonication, centrifugation at 20000 × g for 15 min
and collection of the supernatant. PKMζ was immu-
noprecipitated by incubating the supernatant with 1:50
mouse anti-PKCζ antibody (cat # sc-17781, Santa Cruz
Biotechnology, Santa Cruz, CA) overnight at 4°C. The
samples where then incubated with protein G sepharose
beads (Sigma, St. Louis, MO) for 3 hr at 4°C, followed by
centrifugation and wash with lysis buffer 3 times. The
pelleted beads were suspended in Tris-SDS buffer (1%
SDS and 50 mM Tris–HCl, pH 8.0), centrifuged and the
supernatant was collected. At this stage, the supernatant
contains the immunoprecipitated PKMζ where the nas-
cently synthesized form would have incorporated AHA.
AHA was biotinylated using Click-it Protein Analysis
Detection Kit (Life technologies, Grand Island, NY)according to the manufacturer’s instructions. The bio-
tinylated PKMζ was detected by Western blotting.50m7-GTP pulldown assays
After the protein extraction, 50 μg protein was in-
cubated with 7- methyl GTP Sepharose 4B beads (GE
Healthcare) in the presence of 100uM GTP for 2 h at
4°C. Unconjugated sepharose 4B beads were used for the
negative controls. The beads were then pelleted and
washed twice with lysis buffer. eIF4E, eIF4A and 4EBP
bound to the precipitated beads were analyzed by west-
ern blotting.Western blotting
Fifteen micrograms of protein in 1X Laemmli Sample
Buffer containing 5% v/v β-mercaptoethanol were loaded
in each well and separated by standard 10% SDS-PAGE.
Proteins were transferred to Immobilon-P membranes
(Millipore, Billerica, MA) and then blocked with 5% dry
milk for 3 h at room temperature. The blots were in-
cubated with primary antibody overnight at 4°C and
detected the following day with donkey anti-rabbit anti-
body conjugated to horseradish peroxidase (Jackson Im-
munoresearch, West Grove, PA). Signal was detected by
ECL on chemiluminescent films. PKCλ and PKMζ were
recognized by a pan-aPKC antibody and differentiated
by size. Since PKCζ mRNA was not present in these
tissues, the presence of that protein, the only other
member of the aPKC family, was excluded. Each phos-
phoprotein was normalized to the expression of the cor-
responding total protein on the same membrane. The
p-PKMζ antibody does not recognize p-PKCλ and there-
fore could not be used to determine phosphorylation of
PKCλ. This antibody does recognize p-PKCζ but consist-
ent with an absence of PKCζ in these tissues, no band
was observed at the appropriate size for that protein
with the p-PKC/Mζ antibody. Densitometric analyses
were performed with Image J software (NIH, Bethesda,
MD) using the gel analysis tool available as a plugin from
McMaster University on the following website: macbio-
photonics.ca. Densitometry was done following instruc-
tions given for this plugin for ImageJ.
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IHC on mouse spinal cord was done as described previ-
ously on fresh frozen 20 μm sections of mouse lumbar
spinal cord [63]. Localization of aPKC was assessed with
the Santa Cruz sc-216 antibody and SAP-102 (Cell Signa-
ling Technologies) was used to label neuronal structures.
Primary antibodies and chemicals
The following rabbit antibodies were obtained from Cell
Signaling (Danvers, MA): p-AKT (Ser473, cat# 4058 and
Thr308 cat# 2965), total AKT (cat# 4691), p-mTOR
(Ser2481, cat# 2974), total mTOR (cat# 2983), p-p70
(Thr389, cat# 9205), total p70 (cat# 9202), p-PKC/Mζ
(Thr410, cat# 9378), CaMKIIα (cat# 3357), eIF4A (cat#
2424), 4EBP1/2 (cat# 9452 and 2845) and eIF4E (cat#
9742). Total rabbit aPKC was from Santa Cruz Biotech-
nologies (cat# sc-216, Santa Cruz, CA) and βIII-Tubulin
was from Promega (cat# G7121, Madison, WI). Human
recombinant IL-6, BDNF and TrkB/Fc were from R&D
Systems; myristoyalated CamKIINTide, CamKIINTide
and KN-93 were from Calbiochem; ANA-12 was from
Maybridge; UO126 was from Tocris Bioscience; and
prostaglandin E2 (PGE2) was from Cayman Chemical
Company. Stock solutions of IL-6, CamKIINTide, KN-93,
ANA-12 and UO126 were made in 100% DMSO. BDNF
stock solution was made in sterile PBS containing 0.1%
BSA and TrkB/Fc stock solution was made in sterile PBS.
PGE2 stock solutions were made in 100% ethanol. All
drugs except U0126 and ANA-12 were diluted to final
concentrations in saline for injection. U0126 was diluted
to final concentration in 45% cyclodextrin. ANA-12 was
diluted to final concentration in 10% polyethylene glycol
300. Matching vehicles (saline +matching amount of stock
diluent except for U0126 and ANA-12 where saline
with 45% cyclodextrin or saline with 10% polyethylene
glycol 300, respectively) were used as a control in all
experiments.
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